Back to Search
Start Over
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson's Disease
- Source :
- Journal of Parkinson's disease. 11(3)
- Publication Year :
- 2021
-
Abstract
- Background: Lipopolysaccharide-binding protein (LBP) presents bacterial endotoxin, lipopolysaccharides, to cellular surface pattern receptors for immune responses in the gut-brain axis of Parkinson’s disease (PD). Objective: We investigated whether plasma LBP levels were associated with PD severity and progression. Methods: This study included 397 participants (248 PD patients and 149 controls). We measured participants’ plasma levels of LBP and pro-inflammatory cytokines, including TNF-α, IL-6, andIL-17A. PD patients underwent motor and cognition evaluations at baseline and at a mean follow-up interval of 4.7±2.3 years. We assessed the progression of motor and cognition symptoms based on changes in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III motor score and Mini-Mental State Examination (MMSE) score, respectively. Results: Plasma LBP levels were lower in PD patients than controls (9.08±2.91 vs. 10.10±3.00μg/ml, p
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Parkinson's disease
Disease
Gastroenterology
03 medical and health sciences
Cellular and Molecular Neuroscience
0302 clinical medicine
Rating scale
Internal medicine
Brain-Gut Axis
medicine
Humans
Membrane Glycoproteins
biology
Proportional hazards model
business.industry
Hazard ratio
Confounding
Parkinson Disease
Odds ratio
medicine.disease
030104 developmental biology
biology.protein
Disease Progression
Cytokines
Neurology (clinical)
business
Carrier Proteins
Lipopolysaccharide binding protein
030217 neurology & neurosurgery
Acute-Phase Proteins
Subjects
Details
- ISSN :
- 1877718X
- Volume :
- 11
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of Parkinson's disease
- Accession number :
- edsair.doi.dedup.....7f970f8dc0437a62ec1b164fff153722